Ribociclib Adds Over One Year of Survival in Advanced Breast Cancer

First-line combination therapy reduces risk of death by 24% despite high crossover to CDK4/6 inhibitors in the control arm

Design MONALEESA-2 Phase 3 Trial Population Postmenopausal women with HR+, HER2- advanced breast cancer N 668 Duration Median follow-up 80 months Comparator Placebo + Letrozole Year 2022

Key Performance Indicators

PRIMARY

Hazard Ratio (Death)

0.76

95% CI: 0.63–0.93

Significant survival benefit

PRIMARY

Median OS Gain

+12.5

Months

Clinically meaningful extension

6-Year Survival Rate

44.2%

vs 32.0% Placebo

Long-term benefit

Chemo-Free Survival

39.9

Months (Median)

Delayed toxicity

01

Survival Benefit Widens Over Time

The absolute difference in overall survival rates increases from 5.7% at 4 years to 12.2% at 6 years, demonstrating sustained long-term efficacy.

02

Ribociclib Delays Disease Progression and Chemotherapy

Patients on Ribociclib lived significantly longer and delayed the need for subsequent chemotherapy by nearly a year compared to the placebo group.

03

Survival Benefit is Consistent Across Key Subgroups

The hazard ratio for death favored Ribociclib across most subgroups, including those with visceral metastases (liver/lung) and older patients.

04

Survival Benefit Achieved Despite Higher Post-Trial CDK4/6 Use in Control

Significantly more patients in the placebo arm received a CDK4/6 inhibitor as subsequent therapy, yet the Ribociclib arm still maintained a survival advantage.

05

Neutropenia is the Primary Safety Signal

Grade 3 or 4 neutropenia was markedly higher in the Ribociclib group, consistent with the drug class, while other severe adverse events remained low.

Editorial Conclusion

“Ribociclib plus letrozole demonstrates a statistically significant and clinically meaningful overall survival benefit of over 12 months compared to placebo in the first-line setting.”

Median OS reached 63.9 months, the longest reported in this setting to date.

Benefit was consistent across subgroups and maintained despite higher subsequent CDK4/6 inhibitor use in the placebo arm.

Safety profile remains consistent with known class effects, primarily neutropenia.

Clinical Implication

These results support the use of Ribociclib plus letrozole as a standard-of-care first-line treatment for postmenopausal patients with HR+, HER2- advanced breast cancer.

Reference Data & Sources

Complete Data Table

viz_id	chart_type	label	group	value	low	high	unit	x
viz1	area_chart	48 Months	Ribociclib	60.9			%	48
viz1	area_chart	48 Months	Placebo	55.2			%	48
viz1	area_chart	60 Months	Ribociclib	52.3			%	60
viz1	area_chart	60 Months	Placebo	43.9			%	60
viz1	area_chart	72 Months	Ribociclib	44.2			%	72
viz1	area_chart	72 Months	Placebo	32.0			%	72
viz2	span_chart	Median Overall Survival	Ribociclib	63.9			months
viz2	span_chart	Median Overall Survival	Placebo	51.4			months
viz2	span_chart	Time to First Chemo	Ribociclib	50.6			months
viz2	span_chart	Time to First Chemo	Placebo	38.9			months
viz2	span_chart	Chemo-Free Survival	Ribociclib	39.9			months
viz2	span_chart	Chemo-Free Survival	Placebo	30.1			months
viz3	forest	All Patients	Overall	0.76	0.63	0.93
viz3	forest	Age <65 Yr	Demographics	0.73	0.56	0.94
viz3	forest	Age ≥65 Yr	Demographics	0.81	0.6	1.12
viz3	forest	Visceral Mets (Liver/Lung)	Disease Burden	0.81	0.62	1.05
viz3	forest	Bone Lesion Only	Disease Burden	0.78	0.5	1.21
viz3	forest	ECOG Score 0	Performance Status	0.73	0.56	0.94
viz4	proportional_bar	Subsequent CDK4/6 Inhibitor	Ribociclib Arm	21.7			%
viz4	proportional_bar	Other/No Subsequent CDK4/6	Ribociclib Arm	78.3			%
viz4	proportional_bar	Subsequent CDK4/6 Inhibitor	Placebo Arm	34.4			%
viz4	proportional_bar	Other/No Subsequent CDK4/6	Placebo Arm	65.6			%
viz5	dumbbell	Neutropenia	Ribociclib	63.8			%
viz5	dumbbell	Neutropenia	Placebo	1.2			%
viz5	dumbbell	Hepatobiliary toxicity	Ribociclib	14.4			%
viz5	dumbbell	Hepatobiliary toxicity	Placebo	4.8			%
viz5	dumbbell	Prolonged QT interval	Ribociclib	4.5			%
viz5	dumbbell	Prolonged QT interval	Placebo	2.1			%

Abbreviations

Abbrev	Meaning
OS	Overall Survival
HR	Hazard Ratio
CI	Confidence Interval
CDK4/6	Cyclin-dependent kinases 4 and 6

Source

N Engl J Med 2022;386:942-50

DOI: 10.1056/NEJMoa2114663

Limitations

Black patients were underrepresented (2.5%).
Analysis adjusted for crossover, but high post-progression CDK4/6 use in placebo complicates interpretation.